Abstract/Journal Article DZNE-2020-00799

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
2. Role of astroglial purinergic signaling in Alzheimer’s disease

 ;

2018

Purines 2018 Basic and Translational Science on Purinergic Signaling and its Components for a Healthy and Better World, IguaçuIguaçu, Brazil, 19 Jun 2018 - 22 Jun 20182018-06-192018-06-22 Purinergic signalling 14(1 Supplement), S74 - S75 ()

Abstract: Objectives/background: Astrocytic hyperactivity is a prominent component of network dysfunction in models of Alzheimer’s disease (AD). We havepreviously shown that astrocytic hyperactivity is most pronounced in reactive astrocytes around plaques, and is mediated by purinergic signaling throughthe P2Y1 receptor. The consequences of long-term treatment with a P2Y1R antagonist for network activity, amyloid metabolism and behavior haveremained undetermined. Methods and results: We aimed to study the consequences of long-term P2Y1R inhibition in an AD mouse model. To this end, we administered P2Y1Rantagonists to APPPS1 mice or age-matched littermates intracerebroventricularly using osmotic minipumps. Calcium imaging of neuronal and astroglialactivity in the cortex of anesthetized mice using two-photon microscopy revealed that this treatment reduced astrocytic hyperactivity to levels observed inwildtype mice. Moreover, we found that this treatment augmented structural synaptic integrity and preserved hippocampal long-term potentiation. Theseeffects occurred independently from β-amyloid metabolism and degradation or plaque burden, but were associated with a higher morphologicalcomplexity of peri-plaque reactive astrocytes as well as reduced dystrophic neurite burden. Importantly, APPPS1 mice chronically treated withP2Y1R antagonists were protected from the decline of spatial learning and memory, as measured using the Barnes Maze paradigm. Conclusion: Ourstudy establishes the restoration of cerebral network homoeostasis by P2Y1R inhibition as a novel treatment target in AD. Acknowledgements: Thiswork was supported by grants from the European Union (EU) Joint Programme – Neurodegenerative Disease Research (JPND) program (EU Horizon2020 Research and Innovation Program, grant agreement 643417/DACAPO-AD), the Alzheimer's Research Initiative (Alzheimer Forschung Initiative,AFI), and the DZNE

Classification:

Contributing Institute(s):
  1. Neurovascular Diseases (AG Petzold)
Research Program(s):
  1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2018
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DEAL Springer ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Document types > Presentations > Abstracts
Institute Collections > BN DZNE > BN DZNE-AG Petzold
Public records
Publications Database

 Record created 2020-08-05, last modified 2023-09-15


External link:
Download fulltext
Fulltext
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)